Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in its diagnostics bu...
Discover Revvity’s Q3 2025 earnings, AI-driven innovation, raised EPS guidance, and $1B buyback. Revvity outlines 2%–4% organic growth and $4.90–$5 adjusted EPS guidance as share buybacks accele...
